Front Oncol: Previous anti-vascular treatment may affect the PFS of late-line Anlotinib in the treatment of advanced lung cancer, but does not affect OS and ORR

CSCO guidelines recommend anlotinib for the third-line or above treatment of advanced lung cancer
.

However, whether previous anti- vascular treatments (bevacizumab or endurance) will affect the efficacy of Anlotinib is unclear

CSCO guidelines recommend anlotinib for the third-line or above treatment of advanced lung cancer

The study retrospectively collected clinical data on the use of Anlotinib in the treatment of LC patients, and divided the patients into group A (anlotinib treatment after failure of previous anti-angiogenic drugs) and group B (no anti-angiogenic drug treatment in the past)
.

The study used propensity score matching (PSM) to balance the confounding factors of the two groups

The study retrospectively collected clinical data on the use of Anlotinib in the treatment of LC patients, and divided the patients into group A (anlotinib treatment after failure of previous anti-angiogenic drugs) and group B (no anti-angiogenic drug treatment in the past)

A total of 160 patients were included in the analysis, of which 83 patients had previously received anti-angiogenic therapy (bevacizumab or endurance) (group A), and 77 patients had not previously received anti-angiogenic therapy (group B)

Before PSM, ORR and DCR of group A and group B were 9.

Efficacy evaluation before and after PSM

Efficacy evaluation before and after PSM

For the overall population, the median OS and PFS were 14.
6 months (95%CI 11.
1-18.
1) and 3.
8 months (95%CI 3.
1-4.
5), respectively
.

Before PSM, the median OS of group A and group B were 11.

For the overall population, the median OS and PFS were 14.

Differences in OS before PSM treatment

Differences in OS before PSM treatment

Differences in PFS before PSM treatment

Differences in PFS before PSM treatment

After PSM (n=46), the median OS of the two groups were 14.
6 months and 16.
2 months (P=0.
320), and the median PFS were 3.
5 months and 4.
5 months (P=0.
040)
.

After PSM (n=46), the median OS of the two groups were 14.
6 months and 16.
2 months (P=0.
320), and the median PFS were 3.
5 months and 4.
5 months (P=0.
040)
.

After PSM (n=46), the median OS of the two groups were 14.

            Differences in OS after PSM treatment

Differences in OS after PSM treatment

            Differences in PFS after PSM treatment

            Differences in PFS after PSM treatment

Analysis of previous to antiangiogenic therapy Anluo imatinib treatment study group A further analysis of the data
.

The median PFS of bevacizumab and Endu treatment were 3.

Analysis of previous to antiangiogenic therapy Anluo imatinib treatment study group A further analysis of the data

Multivariate analysis showed that ECOG score (P=0.
002), brain metastasis (P=0.
006) and liver metastasis (P=0.
006) were independent prognostic factors of PFS
.
Multivariate analysis showed that ECOG score (P=0.
002), brain metastasis (P=0.
006) and liver metastasis (P=0.
006) were independent prognostic factors of PFS
.

               Multi-factor analysis of PFS

Multi-factor analysis of PFS

The most common adverse events in group A were skin symptoms (24.
1%), including rash, itching, and hand-foot syndrome, followed by hypertension (8.
4%) and fatigue (6.
0%)
.
Other relatively rare adverse events included vaginal bleeding (3.
6%), nose bleeding (2.
4%) and hematuria (1.
2%)
.
The most common adverse events in group B were skin symptoms (14.
3%), hypertension (10.
4%) and anorexia (10.
4%), followed by diarrhea (7.
8%) and fatigue (7.
8%)
.
Other less common adverse events include: hemoptysis (2.
6%), upper digestive tract bleeding (1.
3%) and stroke (1.
3%)
.

The most common adverse events in group A were skin symptoms (24.
1%), including rash, itching, and hand-foot syndrome, followed by hypertension (8.
4%) and fatigue (6.
0%)
.
Other relatively rare adverse events included vaginal bleeding (3.
6%), nose bleeding (2.
4%) and hematuria (1.
2%)
.
The most common adverse events in group B were skin symptoms (14.
3%), hypertension (10.
4%) and anorexia (10.
4%), followed by diarrhea (7.
8%) and fatigue (7.
8%)
.
Other less common adverse events include: hemoptysis (2.
6%), upper digestive tract bleeding (1.
3%) and stroke (1.
3%)
.
High blood pressure digestion

In summary, studies have shown that previous anti-angiogenic treatments may affect PFS after receiving anlotinib, but may not affect patients' ORR and OS
.

In summary, studies have shown that previous anti-angiogenic treatments may affect PFS after receiving anlotinib, but may not affect patients' ORR and OS
.
Studies have shown that previous anti-angiogenesis treatments may affect PFS after receiving Anlotinib, but may not affect patients' ORR and OS
.
Studies have shown that previous anti-angiogenesis treatments may affect PFS after receiving Anlotinib, but may not affect patients' ORR and OS
.

Original source:

Original source:

Suo J, Sun Y, Fu Y, Xiu W, Zhang X, Wang Y and Zhu J (2021) A Retrospective Analysis of the Effect of Anlotinib in Patients With Lung Cancer With or Without Previous Antiangiogenic Therapy.
Front.
Oncol.
11:788837 .
doi: 10.
3389/fonc.
2021.
788837

Suo J, Sun Y, Fu Y, Xiu W, Zhang X, Wang Y and Zhu J (2021) A Retrospective Analysis of the Effect of Anlotinib in Patients With Lung Cancer With or Without Previous Antiangiogenic Therapy.
Front.
Oncol.
11:788837 .
doi: 10.
3389/fonc.
2021.
788837 leave a message here